SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs REGAL Phase 3 trial reaching its 80-event threshold has shifted attention to the upcoming GPS survival-data readout after database lock and final analysis. Traders are sharply divided: bulls expect a meaningful survival benefit, while skeptics question the trials dosing changes, control-arm outcomes and whether the results will support approval.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons quarterly results put the spotlight on strong AWS growth but also heavy AI infrastructure spending and a sharp free-cash-flow swing, stoking concerns about when the investment will pay off. Traders are split between questioning the cash burn and buying the post-earnings selloff, with many pointing to a sharp rebound as evidence of dip-buying support.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs upcoming Q3 earnings report is the main focus, with traders looking beyond a potential beat to whether guidance can sustain its AI growth story amid a broader pullback in tech stocks. Bulls expect strong results and a raised outlook, while bears argue the valuation leaves little room for an ordinary quarter or disappointing guidance.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins steep selloff ahead of its upcoming earnings report is driving attention, with traders weighing concerns about advertising demand, competition and weakness across ad-tech and software stocks. Bulls argue the decline has outpaced the companys fundamentals and are buying the dip, while bears fear the report or outlook could validate further downside.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA accelerated approval of Voceryq, a competing treatment for recurrent respiratory papillomatosis, has raised concerns about competition for Precigens Papzimeos. Traders debate whether Voceryqs surgery-free dosing will erode demand or whether Papzimeos can retain an advantage through its commercial head start, established payer access, and full approval.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPaths post-earnings selloff and analyst downgrades following its Investor Day are driving discussion, with traders focused on skepticism about slowing growth and whether its agentic-AI push can translate into stronger revenue. Bulls view the companys orchestration products, cash position, and enterprise potential as undervalued, while bears say the business still needs to prove the strategy commercially.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

A third-party photo and commentary identifying POET hardware in Foxconns photonics ecosystem has renewed attention to the FIT collaboration, with traders treating it as validation while debating whether it could lead to production orders; POET has not confirmed new orders. Traders are also weighing reported MarvellLumentum acquisition talks, speculating that optics-sector consolidation could benefit POET as an independent supplier, though others see potential competitive or supply-chain risks.

Invesco DB US Dollar Index Bullish Fund - Invesco DB US Dollar Index Bullish Fund

Invesco DB US Dollar Index Bullish Fund

Shifting expectations for Fed policy and U.S. interest rates are driving discussion of the dollars moves against major currencies. Traders are split between seeing higher yields and rate-hike bets as support for UUP and warning that fiscal concerns and dollar weakness could undermine the trend.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPals Q3 results are driving attention: adjusted earnings beat expectations and full-year guidance rose, while revenue missed and growth remained modest. Traders are split between viewing cash flow and buybacks as support and worrying that weak branded-checkout growth and margin pressure undermine the turnaround; takeover and bank-charter chatter remains speculative.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadog is drawing attention after a sharp pullback amid weakness in software stocks, with traders citing its rich valuation and positioning ahead of the upcoming earnings report. Some view the drop as a buying opportunity and point to call activity, while others expect further downside; no company-specific catalyst is clearly established.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should Vanguard Morningstar Mid-Cap ETF (VO) Be on Your Investing Radar?

ALNY Stock Hits Fresh 52-Week Low On Medicare Access Worries And Pipeline Delays

Equity

Alnylam management said it now expects full-year TTR product sales to land at the low end of its $4.2 billion to $4.5 billion range.


RKLB Stock Slides 8% After Hours As Neutron Debut Slips Into 2027 Over Manufacturing Issues: CEO Says ‘Possible Success Isn’t Our Standard’

Rocket Lab CEO Peter Beck pinned the delay on manufacturing issues identified in the forward propellant dome on the launch vehicle’s first stage. 


MDB Stock Dives After-Hours Despite Raised Full-Year Forecast — What’s Driving The Selloff?

For the current quarter, MongoDB guided to $756 million to $761 million in revenue and $1.57 to $1.61 in adjusted earnings, a step down from the just-finished quarter. 


RDDT Stock Jumps 11% After-Hours — What's Driving The Rally?

Reddit Inc. will replace AvalonBay Communities Inc. (AVB) in the S&P 500 effective prior to the opening of trading on Tuesday, August 18.


RKLB Slips After Hours On Q2 Earnings Miss But Retail Traders Cheer Strong Order Backlog, Upcoming Neutron Launch

Combined with deals signed since Q2 closed, Rocket Lab has already booked more than $1 billion in new launch and space systems contracts, the firm said.


HPE Stock Jumps After Morgan Stanley Upgrade — Analyst Admits ‘We’ve Been On The Wrong Side’ Of The Enterprise Hardware Trade

Morgan Stanley also upgraded its broader U.S. IT Hardware industry view to In-Line from Cautious, citing evidence that the current hardware cycle is being driven by refreshes, pull-forwards and AI demand.


GLW Stock Sank 46% In July, Its Worst Monthly Drop In 24 Years — Truist Sees It As A Buying Opportunity

Corning’s shares ended in the red in 16 out of 22 trading sessions in July, with the stock plummeting in double-digits on three of those days.


RDDT Stock Set For Worst Day On Record — Reddit Advances Copyright Suit Against Perplexity In Crusade Against AI Data Scraping

Federal court clears Reddit to advance anti-circumvention claims against Perplexity AI and SerpApi, even as the platform navigates Google search traffic fluctuations following robust Q2 2026 earnings.


RDDT Stock Is In The Limelight Today After Massive Pre-Market Fall — GOOGL Friction Raises AI Licensing Risks, Says Wells Fargo

The selloff in Reddit shares came as investors looked past the earnings beat and focused on slowing U.S. user growth and management's commentary on its relationship with Google.


Vanguard Index Funds - Vanguard Morningstar Mid-Cap ETF

Bearish Sentiment

<ul class="summary-bullets"><li>CEO Yvonne Greenstreet noted the company is “not yet satisfied with the underlying demand growth” despite expanded sales force efforts.</li><li>CFO Jeff Poulton also flagged potential fourth-quarter ordering volatility as hospitals await a final Centers for Medicare &amp; Medicaid Services (CMS) rule on drug reimbursements.&nbsp;</li><li>Alnylam also said that its mid-stage data for ALN-6400 in hereditary hemorrhagic telangiectasia and early-stage data for ALN-2232 in obesity are now expected in February.</li></ul>Shares of Alnylam Pharmaceuticals (ALNY) fell roughly 26% on Thursday after the company signaled slower-than-expected demand growth for its flagship AMVUTTRA therapy, pushed back certain trial results, and highlighted near-term pressures from Medicare Advantage restrictions and proposed drug reimbursement changes.The stock hit a fresh 52-week low of $172.31 during the session and is on track for its worst day since late July, if the losses hold.<h2 class="st-heading-2">ALNY Flags Concerns</h2>Third-quarter net product revenues rose 52% to about $1.3 billion, driven by total transthyretin (TTR) &nbsp;franchise sales of $1.15 billion. Yet management said it now expects full-year TTR product sales to land at the low end of its $4.2 billion to $4.5 billion range.CEO Yvonne Greenstreet noted the company is “not yet satisfied with the underlying demand growth” despite expanded sales force efforts. Chief Commercialization Officer Tolga Tanguler added that increased physician engagement “has not yet translated into increased demand growth,” citing the time needed to shift entrenched prescribing habits among newer community physicians.On access, Tanguler highlighted a more restrictive first-line AMVUTTRA policy implemented by UnitedHealth in its Medicare Advantage business effective October 1. While existing patients are unaffected and an exception process exists, the change “could create some delays for new patients,” he said.CFO Jeff Poulton also flagged potential fourth-quarter ordering volatility as hospitals await a final Centers for Medicare &amp; Medicaid Services (CMS) rule on drug reimbursements, which, if finalized as proposed, would substantially cut Medicare payments for drugs acquired through the program, such as Alnylam’s Amvuttra, starting in 2027. The company said it will not issue 2027 product revenue guidance at the January JPMorgan conference and will wait until its fourth-quarter results in mid-February.Alnylam also said that its mid-stage data for ALN-6400 in hereditary hemorrhagic telangiectasia and early-stage data for ALN-2232 in obesity are now expected in February with fourth-quarter results, a modest delay from prior guidance of the second half of 2026.<h2 class="st-heading-2">Wall Street Weighs In On ALNY</h2>H.C. Wainwright analyst Patrick Trucchio attributed the stock’s selloff to discussion of Medicare Advantage step-therapy restrictions and potential disruption from changes to drug reimbursement rules. However, the firm views the selloff as an overreaction and reiterated a 'Buy' rating with a $455 price target. It sees the main risk as slower new starts rather than switching of existing patients, and added that it would not equate provider payment changes to an equivalent cut in Alnylam’s realized selling price.Stifel downgraded the stock to 'Hold' from 'Buy' and cut its target to $225 from $318, warning that near-term Amvuttra estimates are likely to come down “probably significantly” and that it is “hard to see a path for the stock with it not being a beat-and-raise story.” Jefferies noted the “slight push” to pipeline catalysts on bleeding and obesity programs and maintains a Hold rating.<h2 class="st-heading-2">How Did ALNY Retail Traders React?</h2>On Stocktwits, retail sentiment around <a class="mention" data-mention="$ALNY" data-symbol-id="ALNY" href="https://stocktwits.com/symbol/ALNY" target="_blank">ALNY stock</a> rose from 'bearish' to 'neutral' territory over the past 24 hours while message volume jumped from 'normal' to 'high' levels.A Stocktwits user noted that the stock is now back to 2023 valuations.<stembedurl>https://stocktwits.com/Olena/message/667661748</stembedurl>ALNY stock has dropped 57% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/cvna-stock-on-track-for-best-day-in-nearly-14-months-as-morgan-stanley-terms-it-top-pick-on-strong-q3-report/cZUQs7pR9R5">CVNA Stock On Track For Best Day In Nearly 14 Months As Morgan Stanley Terms It Top Pick On ‘Strong’ Q3 Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Alnylam Pharmaceuticals logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Alnylam management said it now expects full-year TTR product sales to land at the low end of its $4.2 billion to $4.5 billion range.

Alnylam Pharmaceuticals Inc

Vanguard Mid-Cap ETF

Vanguard Total Stock Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$81.46
Prev Close	$82.24
Open	$82.00
Dividend Yield	N/A
50-Day Moving Average	$80.92
Beta	N/A
Avg. Volume	2.34M
PE Ratio	N/A

52-Week High	$84.59
52-Week Low	$69.44
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

VO Fundamentals